Recent Updates
Recently added Catalysts

Truvada

Phase 3

HIV Infections | Small molecule | Infectious Disease |Gilead Sciences, Inc.|Last Updated: Sep 17, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03512418Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)PHASE3 COMPLETED 30Jun 20, 2019Apr 10, 2024Sep 17, 20251 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Feasibility of the Adherence Intervention Qualitative and Quantitive Questionnaire
three month study visit

Number of participants who were able to complete the trial and record adherence events using the digital pill system in the intervention arm.

Secondary Endpoints
Potential of PrEPsteps to Improve Adherence
three month study visit
Number of People Who Found the Digital Pill Acceptable to Use Within the Intervention Arm
three month visit
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
PrEPstepsEXPERIMENTALParticipants receive the digital pills with Truvada, plus the PrEPsteps intervention that is programmed at the randomization study visit (Study Visit 2). Participants will use PrEPsteps and the digital pill to measure Truvada adherence for months 1-3.
ControlACTIVE_COMPARATORParticipants receive digital pills with Truvada alone. Participants will use digital pills with Truvada for months 1-3.
Interventions
NameTypeDescription
PrEPstepsBEHAVIORALSmartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
Digital pillDEVICEThe digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
TruvadaDRUGParticipants receive once daily Truvada as PrEP to prevent HIV.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Cisgender MSM * Moderate to severe non-alcohol substance use disorder * Self-reported missed PrEP doses (\> or equal to 2 doses in 1 week over past 3 months) * HIV negative * On PrEP or initiating PrEP * Has qualifying laboratory testing: Cr clearance, HBV, liver function test...

Countries:United States
Unlock Eligibility Criteria